Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 5;12(1):4.
doi: 10.1038/s41408-021-00601-5.

Genomic landscape of hyperleukocytic acute myeloid leukemia

Laetitia Largeaud #  1   2   3 , Sarah Bertoli #  2   3   4 , Emilie Bérard #  5   6 , Suzanne Tavitian  4 , Muriel Picard  7 , Stéphanie Dufrechou  1 , Naïs Prade  1 , François Vergez  1   2   3 , Jean Baptiste Rieu  1 , Isabelle Luquet  1 , Audrey Sarry  4 , Françoise Huguet  4 , Jean Ruiz  7 , Véronique De Mas  1   2   3 , Eric Delabesse #  1   2   3 , Christian Récher #  8   9   10
Affiliations

Genomic landscape of hyperleukocytic acute myeloid leukemia

Laetitia Largeaud et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Christian Récher: Research grants (my institution): Abbvie, Amgen, Novartis, BMS-Celgene, Jazz Pharma, Agios, Daiichi-Sankyo, Astellas, Roche, MaatPharma, Iqvia. Advisory boards: Abbvie, Janssen, Jazz Pharma, Daiichi-Sankyo, Astellas, Novartis, Celgene, Takeda, Roche, Otsuka, Macrogenics, Pfizer; Sarah Bertoli: advisory role for Jazz Pharmaceuticals, Daiichi-Sankyo, Sanofi, Astellas and BMS; François Vergez: research grants from Pierre Fabre and Roche; is an advisor for Astellas and Amgen; Françoise Huguet: consultancy Novartis, Pfizer, Incyte; honoraria Amgen, Servier; Isabelle Luquet: advisory role for Jazz Pharmaceuticals.

Figures

Fig. 1
Fig. 1. Mutation pattern in hyperleukocytic AML.
A Number of mutations (grey bars) and patients with mutations (blue bars) per gene. Of the 79 sequenced genes, 44 presented at least one mutation. B Distribution of mutations according to the 2017 European Leukaemia Net classification.
See this image and copyright information in PMC

References

    1. Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125:3246–52. doi: 10.1182/blood-2014-10-551507. - DOI - PubMed
    1. Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020;34:3149–60. doi: 10.1038/s41375-020-0783-3. - DOI - PMC - PubMed
    1. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. doi: 10.1182/blood-2016-08-733196. - DOI - PMC - PubMed
    1. Bullinger L, Dohner K, Dohner H. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol. 2017;35:934–46. doi: 10.1200/JCO.2016.71.2208. - DOI - PubMed
    1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl J Med. 2016;374:2209–21. doi: 10.1056/NEJMoa1516192. - DOI - PMC - PubMed

Publication types

LinkOut - more resources